Recent Updates
Recently added Catalysts
CHER Positive Sentiment

Cheelcare Announces First Quarter Fiscal 2027 Financial Results

Key Takeaway: Cheelcare Inc. reported its financial results for Q1 of fiscal 2027, highlighting the positive impact of Medicare and Medicaid reimbursement eligibility for its Companion product. CEO Eugene Cherny emphasized the growth opportunities stemming from an expanded dealer and clinician network, aiming to convert this into sustained growth. The company also plans to enhance manufacturing efficiency and advance its Curio product towards broader commercialization.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cheelcare has seen the commercial impact of Medicare and Medicaid reimbursement eligibility.
  • The company has expanded its dealer and clinician network, increasing opportunities for growth.
  • Cheelcare is focused on improving manufacturing efficiency and advancing product development.

Full Press Release Details

We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use .
September 25, 2026 8:00 AM EDT | Source: Cheelcare Inc.
Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the three months ended July 31, 2026. All figures are in CAD unless otherwise noted.
Operational Highlights (Three Months Ended July 31, 2026)
First Quarter Financial Highlights (Three Months Ended July 31, 2026)
Subsequent to quarter-end, the Company repaid its outstanding bank loans with the Business Development Bank of Canada in full.
"Q1 is the first full quarter where we are beginning to see the commercial impact of Companion's Medicare and Medicaid reimbursement eligibility in the United States, which was received in January 2026," said Eugene Cherny, CEO of Cheelcare. "That expanded access, together with the growth of our dealer and clinician network, is creating more opportunities to put Companion in the hands of users who can benefit from it. Our focus now is on converting that broader reimbursement access and distribution footprint into sustained Companion growth, continuing to improve manufacturing efficiency as volumes increase, and advancing Curio through the engineering, validation and regulatory work required for broader commercialization."
About Cheelcare Inc. Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic complex-rehab power wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life. For more information, please visit: www.cheelcare.ca .
For further information, please contact: Sofiya Kagan, Director of Marketing Cheelcare Inc. Tel: 1-888-948-2680 x 206 Email: skagan@cheelcare.com
Forward-Looking Information: This news release may contain forward-looking statements. Forward-looking statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied. Such factors include, but are not limited to, general economic conditions, market demand, supply chain disruptions, and regulatory approvals. Any forward-looking statements are made as of the date of this news release, and the Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316019
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Frequently Asked Questions

What were Cheelcare's financial results for Q1 2027?

Cheelcare reported its financial results for Q1 of fiscal 2027, emphasizing growth from Medicare and Medicaid reimbursement.

How has Medicare reimbursement impacted Cheelcare?

The Medicare and Medicaid reimbursement eligibility has positively influenced Cheelcare's commercial growth opportunities.

What is Cheelcare's focus moving forward?

Cheelcare aims to convert expanded reimbursement access into sustained growth and improve manufacturing efficiency.

What products does Cheelcare offer?

Cheelcare designs mobility solutions, including the Companion power assist devices and the Curio robotic wheelchair.

Last updated: Sep 25, 2026